{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:05:53Z","timestamp":1789013153263,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current World Health Organization (WHO) classification of myeloid malignancies includes myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) as a distinct entity. Previous literature on predictors of survival was based on the provisional category of refractory anemia with ring sideroblast and thrombocytosis (RARS-T), which was not subject to MDS\/MPN-RS-T exclusionary criteria such as PB blast% \u22651, BM blast% \u22655 or cytogenetic abnormalities such as t(3;3)(q21.2;q26.2), inv(3)(q21.23q26.2) or isolated del(5q). We examined overall (OS) and leukemia-free (LFS) survival and its predictors, among 158 patients with WHO-defined MDS\/MPN-RS-T. In univariate analysis, age \u226570 years (<jats:italic>P<\/jats:italic>\u2009=\u20090.006), hemoglobin (Hb) \u226410\u2009g\/dL (<jats:italic>P<\/jats:italic>\u2009=\u20090.03) and abnormal karyotype (excluding -Y, <jats:italic>P<\/jats:italic>\u2009=\u20090.008) were associated with shortened OS, which was otherwise not affected by either <jats:italic>ASXL1<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20090.7), <jats:italic>SF3B1 (P<\/jats:italic>\u2009=\u20090.4<jats:italic>)<\/jats:italic> or <jats:italic>JAK2<\/jats:italic> V617F <jats:italic>(P<\/jats:italic>\u2009=\u20090.7<jats:italic>)<\/jats:italic> mutations; in multivariable analysis, Hb\u2009\u2264\u200910\u2009g\/dL (<jats:italic>P<\/jats:italic>\u2009=\u20090.03) and abnormal karyotype (<jats:italic>P<\/jats:italic>\u2009=\u20090.001) remained significant, and thus allowed the development of an operational survival model with low (0 risk factors, median OS 10.5 years), intermediate (1 risk factor, median OS 4.8 years) and high risk (2 risk factors, median OS 1.4 years) categories (<jats:italic>P<\/jats:italic>\u2009=\u20090.0009). Comparison of MDS\/MPN-RS-T (<jats:italic>n<\/jats:italic>\u2009=\u2009158) and MDS\/MPN-U with BM RS\u2009\u2265\u200915% (MDS\/MPN-U-RS; <jats:italic>n<\/jats:italic>\u2009=\u200925) did not reveal significant differences in frequency of thrombosis, OS, or LFS, although <jats:italic>SF3B1<\/jats:italic> mutation frequency was higher in the former (93% versus 59%; <jats:italic>P<\/jats:italic>\u2009=\u20090.0005). These data suggest limited survival impact for molecular abnormalities and the morphological distinction between MDS\/MPN-RS-T and MDS\/MPN-U-RS.<\/jats:p>","DOI":"10.1038\/s41408-022-00622-8","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:02:36Z","timestamp":1643706156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren K.","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla H.","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-213X","authenticated-orcid":false,"given":"Chetasi","family":"Talati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4707-7916","authenticated-orcid":false,"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"622_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood."},{"key":"622_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (Eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer, 2017. p. 82\u201386."},{"key":"622_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"622_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ajh.24637","volume":"92","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92:297\u2013310.","journal-title":"Am J Hematol"},{"key":"622_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ajh.26090","volume":"96","author":"MM Patnaik","year":"2021","unstructured":"Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \u201c2021 update on diagnosis, risk-stratification, and management\u201d. Am J Hematol. 2021;96:379\u201394.","journal-title":"Am J Hematol"},{"key":"622_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ajh.25397","volume":"94","author":"MM Patnaik","year":"2019","unstructured":"Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \u201c2019 Update on Diagnosis, Risk-stratification, and Management\u201d. Am J Hematol. 2019;94:475\u201388.","journal-title":"Am J Hematol"},{"key":"622_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/ajh.24038","volume":"90","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol. 2015;90:549\u201359.","journal-title":"Am J Hematol"},{"key":"622_CR8","first-page":"E246","volume":"96","author":"G Montalban-Bravo","year":"2021","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, et al. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021;96:E246\u2013e249.","journal-title":"Am J Hematol"},{"key":"622_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/hematology.2020000130","volume":"2020","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Lasho TL. Genomics of myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes. Hematol Am Soc Hematol Educ Program. 2020;2020:450\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"622_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/hematology.2020000163","volume":"2020","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Lasho T. Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a focused review. Hematol Am Soc Hematol Educ Program. 2020;2020:460\u20134.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"622_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11899-016-0350-1","volume":"11","author":"C Talati","year":"2016","unstructured":"Talati C, Padron E. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS\/MPN-Unclassifiable, and MDS\/MPN-RS-T. Curr Hematol Malig Rep. 2016;11:425\u201333.","journal-title":"Curr Hematol Malig Rep"},{"key":"622_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","volume":"34","author":"AA Mangaonkar","year":"2020","unstructured":"Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020;34:656\u201361.","journal-title":"Leukemia."},{"key":"622_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ajh.24332","volume":"91","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016;91:492\u20138.","journal-title":"Am J Hematol"},{"key":"622_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","volume":"97","author":"J Broseus","year":"2012","unstructured":"Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97:1036\u201341.","journal-title":"Haematologica."},{"key":"622_CR15","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/sj.leu.2404316","volume":"20","author":"SA Wang","year":"2006","unstructured":"Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006;20:1641\u20134.","journal-title":"Leukemia."},{"key":"622_CR16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adem\u00e0 V, Fuhrmann I, et al. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood. 2020;136:1851\u201362.","journal-title":"Blood"},{"key":"622_CR17","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/leu.2013.120","volume":"27","author":"J Bros\u00e9us","year":"2013","unstructured":"Bros\u00e9us J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27:1826\u201331.","journal-title":"Leukemia."},{"key":"622_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.hoc.2019.11.002","volume":"34","author":"AA Mangaonkar","year":"2020","unstructured":"Mangaonkar AA, Patnaik MM. Treatment of acquired sideroblastic anemias. Hematol Oncol Clin North Am. 2020;34:401\u201320.","journal-title":"Hematol Oncol Clin North Am"},{"key":"622_CR19","doi-asserted-by":"publisher","unstructured":"Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021; https:\/\/doi.org\/10.1038\/s41375-021-01328-9.","DOI":"10.1038\/s41375-021-01328-9"},{"key":"622_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140\u201351.","journal-title":"N Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00622-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00622-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00622-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:02:53Z","timestamp":1669233773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00622-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00622-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"17 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EP has received honoraria and\/or serves on advisory boards of BluePrint, CTI, Stemline Therapeutics, Taiho, and BMS; and has received research funding from Kura, Incyte, and BMS. MP is on the advisory board of Stemline Therapeutics. All other authors declare no relevant conflicts of interest in relation to the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}